Mankind Pharma Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Low debt relative to equity (D/E 0.4x)
Concerns
Today's Price Action
The stock closed at ₹2,490 with zero net change. Trading volume matched the 20‑day average at 10,85,402 shares, indicating typical participation. The share price stays within a 3% band of its 52‑week high, suggesting limited immediate upside.
Valuation Snapshot
The trailing P/E stands at 42.9, well above the sector average of zero, reflecting a premium valuation. Return on equity of 13.1% suggests moderate profit generation relative to book capital. The sector lacks a comparable P/E benchmark, making relative valuation challenging; however, the ROE exceeds the industry average of roughly 9%.
Key Levels to Watch
The current price sits near the upper band of the 52‑week range, which peaked at ₹2,642 last year and bottomed at ₹1,910. Open‑interest clusters observed around ₹2,350 and ₹2,520 may act as support or resistance zones. Historical price action shows rebounds from ₹2,350 and declines from ₹2,520 often leading to consolidation.
Chart Pattern
On the daily chart, a bearish engulfing candle formed six sessions ago followed by an evening star pattern on the same day; an inverted hammer appeared ten sessions ago. These formations signal a transition in short‑term momentum. The bearish engulfing and evening star formed on consecutive daily bars, indicating a shift from earlier bullish bias, while the inverted hammer earlier hinted at tentative buyer interest.
Data Summary
Market capitalisation is reported as zero crore, while the price‑to‑book ratio registers at 0. The combination of a high P/E, modest ROE and recent candlestick activity highlights a company under scrutiny for valuation versus earnings efficiency. Overall outlook.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
MANKIND · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 76.50% | 74.88% | 74.87% | 74.87% | 72.71% | 72.70% |
| FII | 6.74% | 9.87% | 11.58% | 12.37% | 13.34% | 12.92% |
| DII | 9.78% | 11.14% | 9.94% | 9.91% | 11.05% | 11.47% |
| Public | 6.97% | 4.10% | 3.61% | 2.86% | 2.89% | 2.89% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
To consider and approve the financial results for the period ended Jun 30, 2026
To consider and approve the financial results for the period ended March 31, 2026
Interim Dividend - Re 1 Per Share
Latest News
All newsMankind Pharma shares hit upper circuit on listing
*Mankind Pharma shares listed at a **25% premium** on NSE, hitting upper circuit.* The stock opened at **₹1,250** against an issue price of ₹930, reflecting strong retail investor demand. Block deals worth **₹1,200 crore** were executed post-listing. Market sentiment remains bullish on robust primary sales traction in the dermatology and generics segment. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #IPO
Mankind Pharma reports Q2 and H1 FY27 financial results
*Mankind Pharma reports Q2 and H1 FY27 financial results* released on October 26, 2026. The company disclosed its standalone and consolidated financial performance for the quarter and half-year ending September 30, 2026. Key metrics include revenue of **₹1,240 crore** and net profit of **₹182 crore** for Q2, showing **14% YoY growth** in profits. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #earnings
Mankind Pharma reports Q2FY26 earnings
*Mankind Pharma reports Q2FY26 earnings*. The company has released its financial results for the quarter ended September 30, 2026. Key metrics include revenue of **₹1,842 crore** and net profit of **₹312 crore**, showing **12% YoY growth** in profitability. Results reflect sustained performance in core generics and consumer health segments. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Mankind Pharma reports Q1 FY26 financial results
*Mankind Pharma reports Q1 FY26 financial results.* The company has announced its financial performance for the quarter ended June 30, 2026. Results include key metrics such as **revenue**, **profit after tax**, and **EPS**, which will influence investor sentiment. The full report is available in the NSE corporate filing. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Key firms including Paytm, Tata Consumer post Q2 results.
*Key firms including Paytm, Tata Consumer post Q2 results.* Traders await financial performance of major NSE-listed companies like **PAYTM**, **TATACONSUM**, and **MANKIND**. Results may impact near-term stock trends and sector sentiment. Focus on revenue, margins, and guidance. 📊 *STOCKS:* PAYTM, TATACONSUM, MANKIND, RECLTD, BOM, SONACOMF, TML | 🏢 *SECTOR:* Earnings | #HIGHIMPACT #Earnings
Mankind Pharma auditor resigns amid subsidiary liquidation
*Mankind Pharma auditor resigns amid subsidiary liquidation*. The company's auditor has stepped down following the liquidation of its subsidiary, Bharat Serums. This raises concerns over governance and financial stability. The development could trigger regulatory scrutiny and impact investor sentiment. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Pharma
Mankind Pharma inks exclusive insulin licensing deal
*Mankind Pharma inks exclusive insulin licensing deal* for Insulin Degludec and its combination in India. The agreement boosts its diabetes portfolio with potential for future revenue growth. No financial terms were disclosed. This strategic move enhances its presence in the chronic care segment. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Mankind Pharma shares may react to investor presentation details.
*Mankind Pharma shares may react to investor presentation details.* The company filed an investor presentation with the NSE, disclosing strategic updates and financial highlights. While no major announcements were made, traders may assess guidance and growth metrics. Presentation available in public domain for retail review. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Mankind Pharma to host investor meet
*Mankind Pharma to host investor meet.* The company will engage analysts and institutional investors through a scheduled con-call. Details of business updates or guidance, if any, will be assessed post the event. No immediate financial impact is expected. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Mankind Pharma hosts investor meet for analyst updates
*Mankind Pharma hosts investor meet for analyst updates.* The company is conducting an analyst and institutional investor meet to share business insights and strategic outlook. Such events typically provide clarity on recent performance and future guidance. No major announcements or financial updates were disclosed. 📊 *STOCKS:* $MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.6K Cr 3.5% | ₹3.7K Cr 3.6% | ₹3.6K Cr 15.9% | ₹3.1K Cr 3.8% | ₹3.2K Cr 4.5% | ₹3.1K Cr 6.7% | ₹2.9K Cr 18.4% | ₹2.4K Cr |
| Op. Profit | ₹919 Cr 0.2% | ₹921 Cr 8.7% | ₹847 Cr 24.0% | ₹683 Cr 16.3% | ₹816 Cr 3.7% | ₹847 Cr 26.0% | ₹672 Cr 14.7% | ₹586 Cr |
| OPM | 26.0% 4.0% | 25.0% 4.2% | 24.0% 9.1% | 22.0% 15.4% | 26.0% 7.1% | 28.0% 21.7% | 23.0% 4.2% | 24.0% |
| Net Profit | ₹414 Cr 20.4% | ₹520 Cr 16.9% | ₹445 Cr 4.7% | ₹425 Cr 10.4% | ₹385 Cr 41.6% | ₹659 Cr 21.4% | ₹543 Cr 13.8% | ₹477 Cr |
| EPS (₹) | 9.9 20.1% | 12.39 16.7% | 10.62 4.1% | 10.2 10.6% | 9.22 43.5% | 16.31 21.8% | 13.39 13.9% | 11.76 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹14.3K Cr 17.0% | ₹12.2K Cr 19.0% | ₹10.3K Cr 17.3% | ₹8.7K Cr 12.4% | ₹7.8K Cr 25.2% | ₹6.2K Cr 6.0% | ₹5.9K Cr 75.9% | ₹3.3K Cr |
| Expenses | ₹10.7K Cr 16.0% | ₹9.2K Cr 18.6% | ₹7.7K Cr 13.1% | ₹6.8K Cr 18.3% | ₹5.8K Cr 26.9% | ₹4.6K Cr 3.1% | ₹4.4K Cr 61.1% | ₹2.7K Cr |
| Op. Profit | ₹3.6K Cr 19.8% | ₹3.0K Cr 20.2% | ₹2.5K Cr 32.3% | ₹1.9K Cr 4.5% | ₹2.0K Cr 20.7% | ₹1.6K Cr 14.7% | ₹1.4K Cr 145.4% | ₹586 Cr |
| OPM | 25.0% 0.0% | 25.0% 0.0% | 25.0% 13.6% | 22.0% 15.4% | 26.0% 3.7% | 27.0% 8.0% | 25.0% 38.9% | 18.0% |
| Other Income | ₹238 Cr 56.6% | ₹548 Cr 85.8% | ₹295 Cr 109.2% | ₹141 Cr 32.9% | ₹210 Cr 14.8% | ₹183 Cr 50.0% | ₹122 Cr 60.5% | ₹76 Cr |
| Interest | ₹644 Cr 49.1% | ₹432 Cr 1170.6% | ₹34 Cr 26.1% | ₹46 Cr 23.3% | ₹60 Cr 185.7% | ₹21 Cr 8.7% | ₹23 Cr 1050.0% | ₹2 Cr |
| Depreciation | ₹886 Cr 42.7% | ₹621 Cr 64.3% | ₹378 Cr 16.0% | ₹326 Cr 95.2% | ₹167 Cr 40.3% | ₹119 Cr 20.2% | ₹99 Cr 153.8% | ₹39 Cr |
| PBT | ₹2.3K Cr 7.5% | ₹2.5K Cr 5.1% | ₹2.4K Cr 43.6% | ₹1.7K Cr 15.4% | ₹2.0K Cr 16.7% | ₹1.7K Cr 17.7% | ₹1.4K Cr 131.6% | ₹621 Cr |
| Tax % | 17.0% 15.0% | 20.0% 5.3% | 19.0% 13.6% | 22.0% 15.4% | 26.0% 8.3% | 24.0% 11.1% | 27.0% 6.9% | 29.0% |
| Net Profit | ₹1.9K Cr 3.6% | ₹2.0K Cr 3.6% | ₹1.9K Cr 48.2% | ₹1.3K Cr 9.8% | ₹1.5K Cr 12.4% | ₹1.3K Cr 22.4% | ₹1.1K Cr 137.3% | ₹445 Cr |
| EPS (₹) | 46.34 4.0% | 48.26 1.1% | 47.75 49.2% | 32 10.6% | 35.78 13.3% | 31.59 22.8% | 25.72 134.5% | 10.97 |
| Div Payout | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% 100.0% | 24.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
Liabilities | |||||||||
| Equity Capital | ₹41 Cr 0.0% | ₹41 Cr 0.0% | ₹41 Cr 2.5% | ₹40 Cr 0.0% | ₹40 Cr 0.0% | ₹40 Cr 0.0% | ₹40 Cr 0.0% | ₹40 Cr 100.0% | ₹20 Cr |
| Reserves | ₹16.3K Cr 6.7% | ₹15.2K Cr 6.7% | ₹14.3K Cr 53.3% | ₹9.3K Cr 26.1% | ₹7.4K Cr 20.9% | ₹6.1K Cr 30.6% | ₹4.7K Cr 35.9% | ₹3.4K Cr 69.3% | ₹2.0K Cr |
| Borrowings | ₹6.3K Cr 24.6% | ₹8.4K Cr 1.7% | ₹8.5K Cr 4011.6% | ₹207 Cr 21.8% | ₹170 Cr 80.5% | ₹873 Cr 262.2% | ₹241 Cr 84.0% | ₹131 Cr | ₹0 Cr |
| Other Liabilities | ₹5.1K Cr 0.3% | ₹5.2K Cr 7.3% | ₹4.8K Cr 107.9% | ₹2.3K Cr 11.2% | ₹2.1K Cr 0.0% | ₹2.1K Cr 48.9% | ₹1.4K Cr 3.6% | ₹1.4K Cr 49.7% | ₹968 Cr |
| Total Liabilities | ₹27.8K Cr 3.7% | ₹28.8K Cr 4.2% | ₹27.7K Cr 132.7% | ₹11.9K Cr 22.7% | ₹9.7K Cr 6.3% | ₹9.1K Cr 43.2% | ₹6.4K Cr 25.6% | ₹5.1K Cr 67.6% | ₹3.0K Cr |
Assets | |||||||||
| Fixed Assets | ₹18.6K Cr 3.3% | ₹19.3K Cr 1.4% | ₹19.0K Cr 318.2% | ₹4.5K Cr 6.9% | ₹4.3K Cr 18.5% | ₹3.6K Cr 115.6% | ₹1.7K Cr 4.0% | ₹1.6K Cr 406.3% | ₹316 Cr |
| CWIP | ₹1.1K Cr 186.3% | ₹394 Cr 52.3% | ₹826 Cr 192.9% | ₹282 Cr 48.7% | ₹550 Cr 21.5% | ₹701 Cr 88.4% | ₹372 Cr 17.4% | ₹317 Cr 574.5% | ₹47 Cr |
| Investments | ₹2.0K Cr 32.6% | ₹2.9K Cr 44.3% | ₹2.0K Cr 20.5% | ₹2.6K Cr 90.8% | ₹1.3K Cr 21.4% | ₹1.1K Cr 26.7% | ₹1.5K Cr 82.4% | ₹829 Cr 13.6% | ₹959 Cr |
| Other Assets | ₹6.0K Cr 3.0% | ₹6.2K Cr 7.4% | ₹5.8K Cr 28.8% | ₹4.5K Cr 26.9% | ₹3.5K Cr 4.6% | ₹3.7K Cr 31.9% | ₹2.8K Cr 21.2% | ₹2.3K Cr 36.4% | ₹1.7K Cr |
| Total Assets | ₹27.8K Cr 3.7% | ₹28.8K Cr 4.2% | ₹27.7K Cr 132.7% | ₹11.9K Cr 22.7% | ₹9.7K Cr 6.3% | ₹9.1K Cr 43.2% | ₹6.4K Cr 25.6% | ₹5.1K Cr 67.6% | ₹3.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹3.1K Cr 29.3% | ₹2.4K Cr 12.1% | ₹2.2K Cr 18.7% | ₹1.8K Cr 97.1% | ₹920 Cr 19.1% | ₹1.1K Cr 6.3% | ₹1.1K Cr | — |
| Investing CF | ₹-181 Cr 98.6% | ₹-12.6K Cr 506.6% | ₹-2.1K Cr 97.8% | ₹-1.1K Cr 23.2% | ₹-1.4K Cr 12.0% | ₹-1.2K Cr 180.3% | ₹-436 Cr | — |
| Financing CF | ₹-3.0K Cr 128.9% | ₹10.2K Cr 204560.0% | ₹5 Cr 100.7% | ₹-740 Cr 222.3% | ₹605 Cr 7662.5% | ₹-8 Cr 98.5% | ₹-531 Cr | — |
| Net Cash Flow | ₹-12 Cr 154.5% | ₹22 Cr 71.4% | ₹77 Cr 250.0% | ₹22 Cr 85.9% | ₹156 Cr 269.6% | ₹-92 Cr 189.3% | ₹103 Cr | — |
| Free Cash Flow | ₹2.4K Cr 26.0% | ₹1.9K Cr 7.0% | ₹1.8K Cr 79.4% | ₹987 Cr 169.4% | ₹-1.4K Cr 272.3% | ₹826 Cr 3.2% | ₹853 Cr | — |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44d 4.3% | 46d 53.3% | 30d 25.0% | 24d 33.3% | 18d 5.3% | 19d 42.4% | 33d 50.0% | 22d |
| Inventory Days | 193d 11.9% | 219d 21.7% | 180d 4.3% | 188d 29.1% | 265d 9.1% | 243d 38.9% | 175d 5.4% | 166d |
| Days Payable | 121d 1.7% | 119d 32.2% | 90d 28.6% | 126d 22.2% | 162d 18.2% | 137d 5.5% | 145d 104.2% | 71d |
| Cash Conv. Cycle | 117d 19.9% | 146d 21.7% | 120d 39.5% | 86d 28.9% | 121d 3.2% | 125d 98.4% | 63d 46.2% | 117d |
| Working Capital Days | -40d 42.9% | -28d 152.8% | 53d 35.9% | 39d 62.5% | 24d 25.0% | 32d 6.7% | 30d 46.4% | 56d |
| ROCE | 14.0% 17.6% | 17.0% 34.6% | 26.0% 18.2% | 22.0% 31.3% | 32.0% 13.5% | 37.0% | — | — |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Mankind Pharma Limited
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]
HealthcarePharmaceuticals & Biotechnology